Patent · US Active

Kinase modulators for the treatment of cancer

US9617221B2 · kind B2 · utility

0Cited by

1References

4Claims

0Family size

Assignee

SYNOVO GMBH · DE

Inventors

Michael Burnet · Bingen, DE
Jan-Hinrich Guse · Asperg, DE
Christiane Bauerlein · Ofterdingen, DE
Ulrike Hahn · Ditzingen, DE

Key dates

Filing date	Aug 15, 2012
Grant date	Apr 11, 2017
Priority date	—
Expiry date	Dec 20, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07H13/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method of treating cancer in which a compound that inhibits the expression, production or release of IL-10 by immune cells is combined with a compound that stimulates the production of IL-12 when given in combination with, or in the presence of TNFa. Said method is effective when provided in addition to standard therapies, notably chemotherapy using cytotoxic drugs and other forms of immune therapy including therapeutic vaccines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.